Base de dados : MEDLINE
Pesquisa : C10.597.606 [Categoria DeCS]
Referências encontradas : 129 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 129 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11928679
[Au] Autor:Sinczuk-Walczak H
[Ad] Endereço:Przychodni Chorób Zawodowych Instytutu Medycyny Pracy im. prof. J. Nofera w Lodzi.
[Ti] Título:[Nervous system disorders induced by occupational exposure to aluminium compounds: a literature review].
[Ti] Título:Zmiany w ukladzie nerwowym w nastepstwie narazenia zawodowego na zwiazki glinu w swietle pismiennictwa..
[So] Source:Med Pr;52(6):479-81, 2001.
[Is] ISSN:0465-5893
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:This is a review of the literature on the effect of aluminum (Al) and its compounds on the nervous system. The role of aluminum in etiology of some degenerative diseases of the nervous system, e.g. Alzheimer disease, amyotrophic lateral sclerosis or dementia, is presented. The special attention was turned to the effects of aluminum on the nervous system functions in persons occupationally exposed to metal-containing dusts and fumes, manifested mostly by neurobehavioral disorders and changes in the brain bioelectric functions and less frequently pronounced by clinical neurological symptoms.
[Mh] Termos MeSH primário: Alumínio/efeitos adversos
Doenças do Sistema Nervoso Central/induzido quimicamente
Exposição Ocupacional/efeitos adversos
[Mh] Termos MeSH secundário: Doença de Alzheimer/induzido quimicamente
Esclerose Amiotrófica Lateral/induzido quimicamente
Demência/induzido quimicamente
Seres Humanos
Manifestações Neurocomportamentais
Fatores de Risco
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
CPD4NFA903 (Aluminum)
[Em] Mês de entrada:0206
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020404
[St] Status:MEDLINE


  2 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11577910
[Au] Autor:Orbach I; Stein D; Shan-Sela M; Har-Even D
[Ad] Endereço:Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel. orbachi@mail.biu.ac.il
[Ti] Título:Body attitudes and body experiences in suicidal adolescents.
[So] Source:Suicide Life Threat Behav;31(3):237-49, 2001.
[Is] ISSN:0363-0234
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The relationships between cognitive and affective attitudes toward the body, body experiences (dissociation, insensitivity, and lack of control), and suicidal tendencies were examined as a derivative of the hypothesis that bodily attitudes and experiences may facilitate suicidal acting out. Three groups of adolescents (aged 14-18), including suicidal (made a suicide attempt) and nonsuicidal inpatients and controls, were compared with regard to suicidal tendencies, various body aspects, and depression and anxiety. A series of MANOVAs, discriminant analysis, Pearson correlations, and regressions were employed. The results show that the suicidal group differed from the two nonsuicidal groups in feelings toward the body, body protection, and body dissociation. Some aspects of bodily measures discriminated between suicidal and nonsuicidal subjects. In addition, various bodily measures were associated with and statistically predicted suicidal tendencies. The discussion focuses on the web of associations between body attitudes and experiences and their role in suicidal behavior.
[Mh] Termos MeSH primário: Comportamento do Adolescente/psicologia
Sintomas Comportamentais/psicologia
Transtorno Depressivo/psicologia
Suicídio/psicologia
[Mh] Termos MeSH secundário: Adolescente
Análise de Variância
Imagem Corporal
Feminino
Seres Humanos
Acontecimentos que Mudam a Vida
Masculino
Manifestações Neurocomportamentais
Valor Preditivo dos Testes
Escalas de Graduação Psiquiátrica
Distribuição por Sexo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:0201
[Cu] Atualização por classe:061115
[Lr] Data última revisão:
061115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:011002
[St] Status:MEDLINE


  3 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11563830
[Au] Autor:Bieber EJ; Cohen DP
[Ad] Endereço:University of Chicago, Pritzker School of Medicine, Illinois 60637, USA.
[Ti] Título:Estrogens and hormone replacement therapy: is there a role in the preservation of cognitive function?
[So] Source:Int J Fertil Womens Med;46(4):206-9, 2001 Jul-Aug.
[Is] ISSN:1534-892X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Alzheimer's disease affects as many as 40% of Americans over the age of 80 and, as such, is a major public health issue. Interestingly, there is a two- to threefold greater prevalence in women than in men. It has been estimated that the prevalence of Alzheimer's disease will quadruple over the next half century. There have been implications of an effect of estrogen on neurological function for many years. As long as 50 years ago a study published in the gerontology literature suggested that the administration of i.m. estrogen in a nursing home population was associated with improvement in memory and a delay in progression of memory loss. Most recently there has been great interest in the effect of estrogen on both neurons and the CNS vasculature. A study evaluating verbal memory and abstract reasoning in over 700 women without dementia demonstrated that women who had used estrogen for as little as 1 year had significant improvements in baseline cognitive testing. The pathogenesis of Alzheimer's disease and neurodementia is better understood today but remains incompletely elucidated. It has been suggested that inflammation exists both within the neurovasculature and the stroma and that beta-amyloid creates an inflammatory reaction. In Alzheimer's patients there are abnormal deposits of proteins such as beta-amyloid, presenelin, and apolipoprotein E-4. Estrogen may act as a protectant against these inflammatory mediating proteins. While a recent trial demonstrated no impact of estrogen in patients diagnosed with mild to moderate Alzheimer's, other studies have suggested that estrogen use significantly delays disease onset. One study followed over 1,100 subjects who were free of disease at trial initiation over a period of 1 to 5 years. Even short-term use of estrogen imparted protection, although longer-term estrogen use was associated with greater protection. Unfortunately, most women are unaware of the potential beneficial effect of estrogen on cognitive function. Prospective studies are under way to try to delineate how estrogen impacts Alzheimer's disease.
[Mh] Termos MeSH primário: Doença de Alzheimer/prevenção & controle
Estrogênios/uso terapêutico
Terapia de Reposição Hormonal
Manifestações Neurocomportamentais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Doença de Alzheimer/tratamento farmacológico
Ensaios Clínicos como Assunto
Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Estrogens)
[Em] Mês de entrada:0201
[Cu] Atualização por classe:071115
[Lr] Data última revisão:
071115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010921
[St] Status:MEDLINE


  4 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11532642
[Au] Autor:Glosser G
[Ad] Endereço:Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
[Ti] Título:Neurobehavioral aspects of movement disorders.
[So] Source:Neurol Clin;19(3):535-51, v, 2001 Aug.
[Is] ISSN:0733-8619
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cognitive, behavioral, affective, and psychiatric symptoms occur in almost all movement disorders. Diagnosis and management of movement disorders depends critically on an understanding of these neurobehavioral symptoms. This article reviews the neurobehavioral aspects of two representative movement disorders; Parkinson's disease and Huntington's disease.
[Mh] Termos MeSH primário: Doença de Huntington/psicologia
Manifestações Neurocomportamentais
Doença de Parkinson/psicologia
[Mh] Termos MeSH secundário: Transtornos Cognitivos/etiologia
Demência/etiologia
Seres Humanos
Doença de Huntington/complicações
Transtornos do Humor/etiologia
Doença de Parkinson/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:0110
[Cu] Atualização por classe:051116
[Lr] Data última revisão:
051116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010905
[St] Status:MEDLINE


  5 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11449032
[Au] Autor:Hinkin CH; Castellon SA; Hardy DJ; Farinpour R; Newton T; Singer E
[Ad] Endereço:Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles 90024, USA. chinkin@ucla.edu
[Ti] Título:Methylphenidate improves HIV-1-associated cognitive slowing.
[So] Source:J Neuropsychiatry Clin Neurosci;13(2):248-54, 2001.
[Is] ISSN:0895-0172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sixteen HIV-1 seropositive individuals participated in a single-blind, placebo-controlled, crossover-design study of the effectiveness of 30 mg/ day of methylphenidate (MPH) in the treatment of HIV-associated cognitive slowing. Regression analyses revealed that participants who entered the study with a greater degree of either depressive symptomatology or cognitive slowing tended to demonstrate a better response to MPH on computerized measures of choice and dual-task reaction time. Participants without evidence of cognitive slowing at study entry did not show greater improvement on MPH than on placebo. Contrary to expectation, symptoms of depression did not respond better to MPH than to placebo, regardless of initial symptomatology. Information processing slowing in HIV-1 infection therefore appears amenable to pharmacologic intervention with the dopamine agonist MPH. However, results suggest clinicians should consider reserving the use of MPH for patients with more pronounced cognitive and affective deficits.
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/uso terapêutico
Transtornos Cognitivos/tratamento farmacológico
Soropositividade para HIV/complicações
HIV-1
Metilfenidato/uso terapêutico
Manifestações Neurocomportamentais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Transtornos Cognitivos/etiologia
Estudos Cross-Over
Feminino
Seres Humanos
Masculino
Meia-Idade
Escalas de Graduação Psiquiátrica
Psicometria
Tempo de Reação
Método Simples-Cego
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:0109
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010713
[St] Status:MEDLINE


  6 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11449029
[Au] Autor:Murai T; Müller U; Werheid K; Sorger D; Reuter M; Becker T; von Cramon DY; Barthel H
[Ad] Endereço:Max Planck Institute of Cognitive Neurosciences, Lepzig, Germany. murai@kuhp.kyoto-u.ac.jp
[Ti] Título:In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.
[So] Source:J Neuropsychiatry Clin Neurosci;13(2):222-8, 2001.
[Is] ISSN:0895-0172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Parkinson's disease affects various neurotransmitter systems. Using SPECT, the authors measured [(123)I]beta-CIT binding ratios of the caudate, putamen, medial thalamus, and dorsal midbrain over cerebellum in 16 patients with Parkinson's disease, and examined correlations with clinical ratings. Whereas striatal binding ratios (reflecting regional dopamine transporter densities) were associated with motor symptoms, dorsal midbrain binding ratios (reflecting regional serotonin transporter densities) were significantly correlated with the mentation, behavior, and mood subscale of the Unified Parkinson's Disease Rating Scale. These findings indicate that degeneration of the nigrostriatal dopaminergic neurons and a dysfunctional serotonergic raphe system contribute differentially to motor deficits and neuropsychiatric symptoms in Parkinson's disease.
[Mh] Termos MeSH primário: Corpo Estriado/metabolismo
Dopamina/metabolismo
Mesencéfalo/metabolismo
Doença de Parkinson/psicologia
Serotonina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Corpo Estriado/diagnóstico por imagem
Feminino
Seres Humanos
Processamento de Imagem Assistida por Computador
Masculino
Mesencéfalo/diagnóstico por imagem
Meia-Idade
Manifestações Neurocomportamentais
Testes Neuropsicológicos
Doença de Parkinson/diagnóstico por imagem
Doença de Parkinson/metabolismo
Escalas de Graduação Psiquiátrica
Núcleos da Rafe/metabolismo
Substância Negra/metabolismo
Tomografia Computadorizada de Emissão de Fóton Único
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
333DO1RDJY (Serotonin); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:0109
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010713
[St] Status:MEDLINE


  7 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11401021
[Au] Autor:Deschamps D; Géraud C; Dally S
[Ad] Endereço:Department of Internal Medicine and Clinical Toxicology, Hospital Fernand Widal, Paris, France. dally@ext.jussieu.fr
[Ti] Título:Cognitive functions in workers exposed to toluene: evaluation at least 48 hours after removal from exposure.
[So] Source:Int Arch Occup Environ Health;74(4):285-8, 2001 May.
[Is] ISSN:0340-0131
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Long-term exposure to toluene may result in subtle impairment of cognitive functions. However, it is not clear whether this impairment is due to the presence of the solvent in the body or if it persists after its elimination from blood. The aim of this study is to compare cognitive functions between toluene-exposed workers (at least 48 h after removal from exposure) and non-exposed workers. METHODS: Seventy-two workers exposed for at least 5 years to toluene (9 to 467 ppm) completed a questionnaire and psychometric tests. The results were compared with those of 61 non-exposed workers. An alveolar air sample was taken just before the tests to ensure the absence of toluene. RESULTS: Results of the vocabulary test were slightly better in exposed (correct words: 21 +/- 0.6) than in non-exposed workers (19 +/- 0.8) (P < 0.05). No differences were found for simple reaction time, digit symbol, digit span, continuous tracking test, color word and switching attention test. CONCLUSIONS: The results of this study do not support the notion of the persistence of cognitive effects of toluene after elimination of the solvent from blood.
[Mh] Termos MeSH primário: Cognição/efeitos dos fármacos
Solventes/efeitos adversos
Tolueno/efeitos adversos
[Mh] Termos MeSH secundário: Interpretação Estatística de Dados
Feminino
Seres Humanos
Masculino
Meia-Idade
Manifestações Neurocomportamentais
Exposição Ocupacional
Psicometria
Inquéritos e Questionários
Fatores de Tempo
Tolueno/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Solvents); 3FPU23BG52 (Toluene)
[Em] Mês de entrada:0111
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010613
[St] Status:MEDLINE


  8 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11271983
[Au] Autor:O'Mahony S; Coyle N; Payne R
[Ad] Endereço:Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. soma906458@aol.com
[Ti] Título:Current management of opioid-related side effects.
[So] Source:Oncology (Williston Park);15(1):61-73, 77; discussion 77-8, 80-2, 2001 Jan.
[Is] ISSN:0890-9091
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The optimal management of opioid-related side effects is hampered by a lack of comparative studies of management strategies. The prevalence of such side effects is influenced by the extent of disease, the patient's age, the presence of coexistent renal and hepatic disease, pulmonary disease, and cognitive dysfunction, a prior opioid history, use of polypharmacy, dose of opioid drug being administered, and the route of administration. The most common opioid-related side effects are constipation, sedation, nausea, vomiting, and cognitive disturbance. Less frequent side effects include urinary retention, perceptual distortion, respiratory depression, and myoclonus. In an era emphasizing quality of life in cancer care, clinicians need to be aware of (1) factors that influence the prevalence of opioid-related side effects, (2) effective management strategies, and (3) how to recognize when symptoms are opioid related as opposed to caused by other etiologies, such as the patient's disease process or treatment approaches. The use of validated instruments and repeated assessment enhances such an evaluation and subsequent treatment. This article delineates the current optimal management of opioid-related nausea and vomiting, constipation, cognitive side effects, myoclonus, and respiratory depression.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Antieméticos/uso terapêutico
Catárticos/uso terapêutico
Constipação Intestinal/prevenção & controle
Náusea/prevenção & controle
Vômito/prevenção & controle
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Antipsicóticos/uso terapêutico
Constipação Intestinal/induzido quimicamente
Seres Humanos
Náusea/induzido quimicamente
Manifestações Neurocomportamentais
Receptores Opioides/metabolismo
Medição de Risco
Vômito/induzido quimicamente
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Antiemetics); 0 (Antipsychotic Agents); 0 (Cathartics); 0 (Receptors, Opioid)
[Em] Mês de entrada:0104
[Cu] Atualização por classe:061115
[Lr] Data última revisão:
061115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010329
[St] Status:MEDLINE


  9 / 129 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11201991
[Au] Autor:Conquer JA; Tierney MC; Zecevic J; Bettger WJ; Fisher RH
[Ad] Endereço:Department of Human Biology and Nutritional Sciences, University of Guelph, Ontario, Canada. jconquer@uoguelph.ca
[Ti] Título:Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.
[So] Source:Lipids;35(12):1305-12, 2000 Dec.
[Is] ISSN:0024-4201
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Fatty acid differences, including docosahexaenoic acid (DHA; 22:6n-3) have been shown in the brains of Alzheimer's patients (AD) as compared with normal age-matched individuals. Furthermore, low serum DHA is a significant risk factor for the development of AD. The relative concentration of DHA and other fatty acids, however, in the plasma of AD patients compared with patients with other kinds of dementias (other dementias; OD), patients who are cognitively impaired but nondemented (CIND), or normal patients is not known. In this study we analyzed the total phospholipid, phosphatidylcholine (PC), phosphatidylethanolamine (PE), and lysophosphatidylcholine (lysoPC) fractions of plasma from patients diagnosed with AD, OD, or CIND and compared them with a group of elderly control subjects with normal cognitive functioning. Plasma phospholipid and PC levels of 20:5n-3, DHA, total n-3 fatty acids, and the n-3/n-6 ratio were lower in the AD, OD, and CIND groups. Plasma phospholipid 24:0 was lower in the AD, OD, and CIND groups as compared with the group of control patients, and total n-6 fatty acid levels were higher in the AD and CIND groups only. In the plasma PE fraction, levels of 20:5n-3, DHA, and the total n-3 fatty acid levels were significantly lower in the AD, OD, and CIND groups. DHA levels were lower in the lysoPC fraction of CIND individuals only. There were no other differences in the fatty acid compositions of the different phospholipid fractions. Therefore, in AD, OD, and CIND individuals, low levels of n-3 fatty acids in the plasma may be a risk factor for cognitive impairment and/or dementia. Interestingly, a decreased level of plasma DHA was not limited to the AD patients but appears to be common in cognitive impairment with aging.
[Mh] Termos MeSH primário: Doença de Alzheimer/sangue
Demência/sangue
Ácidos Graxos/sangue
Manifestações Neurocomportamentais
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Encéfalo/metabolismo
Estudos de Casos e Controles
Ácidos Docosa-Hexaenoicos/sangue
Feminino
Seres Humanos
Lisofosfatidilcolinas/sangue
Masculino
Fosfatidilcolinas/sangue
Fosfatidiletanolaminas/sangue
Fosfolipídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fatty Acids); 0 (Lysophosphatidylcholines); 0 (Phosphatidylcholines); 0 (Phosphatidylethanolamines); 0 (Phospholipids); 25167-62-8 (Docosahexaenoic Acids)
[Em] Mês de entrada:0105
[Cu] Atualização por classe:171105
[Lr] Data última revisão:
171105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010224
[St] Status:MEDLINE


  10 / 129 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:11100947
[Au] Autor:Sethre T; Läubli T; Hangartner M; Berode M; Krueger H
[Ad] Endereço:Institute of Hygiene and Applied Physiology, Zürich, Switzerland. sethre@iha.bepr.ethz.ch
[Ti] Título:Isopropanol and methylformate exposure in a foundry: exposure data and neurobehavioural measurements.
[So] Source:Int Arch Occup Environ Health;73(8):528-36, 2000 Nov.
[Is] ISSN:0340-0131
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to determine the dose-effect relationship between solvent exposure and acute neurobehavioural effects at the worksite. METHODS: In a balanced design, ten workers in a Swiss foundry were monitored for 15 days at ten different times during work. Urine samples were taken in the morning and at the time of examination, and personal exposure to isopropanol and methylformate was measured with active samplers. Neurobehavioural tests such as postural balance (bipedal, bipedal blind, monopedal), simple reaction time and digit span of the Neurobehavioural Evaluation System (NES2) and a combined memory and reaction-time test, the combi-test, were performed. A rating of well-being, and the last consumption of alcohol, caffeine, nicotine and medication were reported. RESULTS: Average environmental concentrations of isopropanol were at 44 ppm ( +/- 16 ppm), and at 36 ppm (+/-21 ppm) for methylformate. Maximum values of personal exposure to isopropanol reached barely the maximal allowable concentration (MAC) value (400 ppm); the methylformate personal exposure of three workers exceeded the MAC value (100 ppm). Urine concentrations of methanol were high (3.1 +/- 2.3 mg/l in the morning, 7.8 +/- 4.9 mg/l after exposure) compared with the results of other studies; concentrations of isopropanol were rather low (0.88 +/- 0.73 mg/l after exposure). CONCLUSIONS: Nevertheless, between personal exposure and biomonitoring, linear correlation was found. Methylformate exposure correlated with methanol and formic acid concentration in the urine, and isopropanol exposure with its concentration in the urine. With the neurobehavioural tests used, no solvent effect in relation to the dose could be determined.
[Mh] Termos MeSH primário: 2-Propanol/efeitos adversos
Poluentes Ocupacionais do Ar/efeitos adversos
Ésteres do Ácido Fórmico/efeitos adversos
Metalurgia
Exposição Ocupacional
Solventes/efeitos adversos
[Mh] Termos MeSH secundário: 2-Propanol/urina
Monitoramento Ambiental
Formiatos/urina
Seres Humanos
Masculino
Concentração Máxima Permitida
Metanol/urina
Manifestações Neurocomportamentais
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Air Pollutants, Occupational); 0 (Formates); 0 (Formic Acid Esters); 0 (Solvents); 0YIW783RG1 (formic acid); 1MPH591FTG (methyl formate); ND2M416302 (2-Propanol); Y4S76JWI15 (Methanol)
[Em] Mês de entrada:0102
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:001202
[St] Status:MEDLINE



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde